One pivotal trial, the new default option for FDA approval — ending the two-trial dogma

New England Journal of Medicine

18 February 2026 - This Sounding Board announces a new FDA policy that the default requirement for FDA approvals will be one robust pivotal trial plus confirmatory evidence, rather than two trials.

Read New England Journal of Medicine Sounding Board

Michael Wonder

Posted by:

Michael Wonder